InnovaVector
Private Company
Funding information not available
Overview
InnovaVector is a young but experienced CDMO focused exclusively on AAV vector services, positioning itself as a critical enabler for gene therapy developers. Its key differentiator is its direct lineage from the renowned TIGEM and Alberto Auricchio's lab, providing a strong foundation of proprietary plasmids, cell banks, and manufacturing platforms. The company is building a full-service offering from discovery to GMP production, targeting the rapidly growing global gene therapy sector. Based in Milan, it is a private, likely pre-revenue or early-revenue company serving biotech and pharma clients.
Technology Platform
Proprietary AAV manufacturing platform leveraging IP from TIGEM, including proprietary plasmids, cell banks, and expertise in both adherent and suspension cell culture systems for production and purification of a wide range of AAV serotypes.
Opportunities
Risk Factors
Competitive Landscape
InnovaVector competes in the viral vector CDMO space against large multinationals (e.g., Lonza, Catalent, Thermo Fisher's Brammer Bio) and a growing number of specialized firms (e.g., Vigene, Aldevron, Genezen). Its differentiation lies in its focused AAV expertise, proprietary technology from TIGEM, and its European base, appealing to sponsors seeking a specialized, agile partner.